Multicentric evaluation of the Bio-Evolution Toxoplasma gondii assay for the detection of Toxoplasma DNA in immunocompromised patients.
Background: PCR-based methods are a key tool for the diagnosis of toxoplasmosis in immunocompromised patients. Laboratory-developed protocols lack standardization. This study aimed to assess the performances of a commercial kit for the detection of Toxoplasma DNA in different specimens drawn from immunocompromised patients.Material/methods: This multicentric retrospective study included 227 DNA specimens (157 blood samples, 22 broncho-alveolar fluids (BALF), 39 cerebrospinal fluids (CSF) and 9 miscellaneous), collected between 2010 and 2015 from 126 immunocompromised patients. Those specimens were selected based on previous laboratory-developed qPCR results targeting either rep529 element or B1 gene, and classified as positive, negative and, "negative of interest"; the latter defined as either the last negative specimen before a positive one or the first negative specimen following positive specimen(s). All specimens were secondary tested using the Bio-Evolution Toxoplasma DNA assay targeting the T. gondii rep529 element.Results: We found a 95.6% concordance rate for qualitative results obtained with laboratory-developed qPCR techniques and the commercial kit. The rate reached 99.3% when comparing rep529-based laboratory-developed PCR methods and the commercial kit. The relative quantifications between the commercial kit and the rep529 laboratory-developed PCRs were in very good agreement. Sensitivity and specificity of the commercial kit were calculated at 98.8% and 100% respectively.Conclusion: The Bio-Evolution Toxoplasma DNA assay appears as a valuable method for the detection of Toxoplasma DNA in blood, BALF and CSF from immunocompromised patients.